Intranasal Delivery of Hypoxia Primed Whartons Jelly MSC Derived sEVs Reprograms Neuroimmune Signalling and Ameliorates Behavioural Deficits in a Valproic Acid Induced Mouse Model of Autism Spectrum Disorder
This study demonstrates that intranasal delivery of hypoxia-primed Wharton's jelly mesenchymal stem cell-derived small extracellular vesicles (WJ-H-sEVs) effectively ameliorates behavioral deficits and neuroinflammation in a valproic acid-induced mouse model of autism spectrum disorder by reprogramming neuroimmune signaling through the activation of the Nrf2 pathway and suppression of NF-κB and JAK-STAT signaling.